MS Research Spotlight: Biomarkers Identified, Smoldering Inflammation, and More
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The MultipleSclerosis.net team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
- Olga Ciccarelli, Multiple sclerosis in 2018: new therapies and biomarkers, The Lancet Neurology, Volume 18, Issue 1, 2019, Pages 10-12, https://doi.org/10.1016/S1474-4422(18)30455-1. (http://www.sciencedirect.com/science/article/pii/S1474442218304551)
- Jacobs S. Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis. Neurology Advisor. https://www.neurologyadvisor.com/multiple-sclerosis/no-evidence-of-disease-activity-neda-3-and-disability-improvement-with-alemtuzumab-ms/article/823868/. Published January 1, 2019. Accessed January 10, 2019.
- Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment Koskimäki F, Bernard J, Yong J, Arndt N, Carroll T, et al. (2018) Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. PLOS ONE 13(12): e0209326. https://doi.org/10.1371/journal.pone.0209326
- Elliott C, Wolinsky JS, Hauser SL, et al. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Multiple Sclerosis Journal. 2018:135245851881411. doi:10.1177/1352458518814117.